Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr;3(2):306-9.
doi: 10.4103/0975-7406.80767.

Does atorvastatin work more effectively than biguanides in reducing cardiovascular risk factors?

Afshan Siddiq  1 , Rafeeq Alam Khan, Sadia Ghousia Baig
Affiliations

Does atorvastatin work more effectively than biguanides in reducing cardiovascular risk factors?

Afshan Siddiq et al. J Pharm Bioallied Sci. 2011 Apr.

Abstract

Increased risk of coronary artery disease in diabetic persons is associated with increased level of lipoproteins. Usually, such risks are reverted with glycemic control by antidiabetic medicines in Type I diabetes millitus. However, in Type II diabetes mellitus lipid values can be improved using antidiabetics but still the risk of coronary artery disease remains. The initial approach for reducing lipid contents in diabetic patients should include glycemic control, diet, weight loss, and exercise. But if it fails then lipid-lowering agents like fibrate and HMG CoA reductase (3-hydroxy-3-methyl-glutaryl-CoA reductase) inhibitors should work effectively. In the present study results of atorvastatin compared with biguanides proved atorvastatin as a more effective lipid-lowering agent along with antidiabetic activity so it can effectively help in reducing the risk of cardiovascular disease (CVD).

Keywords: 3-hydroxy-3-methyl-glutaryl-CoA reductase; Atorvastatin; biguanides; cardiovascular disorders.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Effect on the weight of the test groups and their comparison with control
Figure 2
Figure 2
Variation in the serum glucose level and HBA1C of the test groups with respect to control
Figure 3
Figure 3
Variation and comparison in lipid contents of drugs
See this image and copyright information in PMC

References

    1. Muller DC, Elahi D, Tobin JD, Andres R. The effect of age on insulin resistance and secretion: A review. Semin Nephrol. 1996;16:289–98. - PubMed
    1. Haffner SM. Management of Dyslipidemia in Adults with Diabetes. Diabetes Care. 2003;26:S83–6. - PubMed
    1. Gray RS, Fabsitz RR, Cowan LD, Lee ET, Howard BV, Savage PJ. Risk factor clustering in the insulin resistance syndrome.The Strong Heart Study. Am J Epidemiol. 1998;148:869–78. - PubMed
    1. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183–202. - PubMed
    1. Pimenta W, Korytkowski M, Mitrakou A, Jenssen T, Yki-Jarvinen H, Evron W, et al. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM.Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA. 1995;273:1855–61. - PubMed